A medical trial screening a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy grownups discovered that it was safe and promoted both antibodies and actions from the cellular arm of the immune system. The speculative vaccine, ID93+ GLA-SE, was established by Christopher B. Fox, Ph.D., and scientists at the Access to Advanced Health Institute (previously the Infectious Disease Research Institute) in Seattle. Daniel F. Hoft, M.D., Ph.D., director of the Saint Louis University Center for Vaccine Development, led the single-site trial at the universitys School of Medicine. It is not possible to state whether the boosted immune responses seen in the thermostable vaccine formulation would translate to improved protective vaccine effectiveness.
Daniel F. Hoft, M.D., Ph.D., director of the Saint Louis University Center for Vaccine Development, led the single-site trial at the universitys School of Medicine. Both vaccine presentations were safe and well-tolerated.
The private investigators keep in mind some constraints in this little trial. It is not possible to say whether the improved immune responses seen in the thermostable vaccine formulation would translate to improved protective vaccine efficacy.
Reference: “Safety and immunogenicity of a thermostable formula of the ID93 + GLA-SE tuberculosis vaccine candidate in healthy grownups” by ZK Sagawa et al., 6 March 2023, Nature Communications.DOI: 10.1038/ s41467-023-36789-2.
Scanning electron micrograph of Mycobacterium tuberculosis germs, which trigger TB, colorized. Credit: NIAID
A medical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy grownups discovered that it was safe and promoted both antibodies and actions from the cellular arm of the body immune system. The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. A non-temperature stable kind of the prospect formerly had been checked in a number of clinical trials. This was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) type. Results will be released today (March 6, 2023) in the journal Nature Communications.
The speculative vaccine, ID93+ GLA-SE, was developed by Christopher B. Fox, Ph.D., and researchers at the Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) in Seattle. The freeze-dried formula does not need refrigeration and is mixed with sterile water just prior to injection.
The current trial examined whether administering temperature-stable vaccine including both ID93 and GLA-SE in a single vial would be as reliable at inducing an immune action as a regimen in which non-thermostable ID93 and liquid GLA-SE are held in two vials and combined prior to injection. A single-vial presentation of a thermostable vaccine would have clear advantages in ease of transport, storage and administration, the detectives keep in mind.
